RO7297089/AFM26 is another TandAb directed against BCMA whose efficacy as single agent in a phase 1 trial with R/R MM patients (NCT04434469) was not as solid as previously reported with BCMA-targeted TCE [117]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.